Pyrazolopyridine antiherpetics: SAR of C2′ and C7 amine substituents

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 7, 2005, Pages 2397-2411

  Johns, Brian A ^a   Gudmundsson, Kristjan S ^a   Turner, Elizabeth M ^a   Allen, Scott H ^a   Samano, Vicente A ^a   Ray, John A ^a   Freeman, George A ^a   Boyd Jr , F Leslie ^a   Sexton, Connie J ^a   Selleseth, Dean W ^a   Creech, Katrina L ^a   Moniri, Kelly R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Antiherpetic; HSV; Pyrazolo 1,5 a pyridine

Indexed keywords

3 (2 AMINO 4 PYRIMIDINYL) N CYCLOPENTYL 2 (4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 (2 ANILINO 4 PYRIMIDINYL) N CYCLOPENTYL 2 (4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL) N (2 METHOXYETHYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL) N METHYLPYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL) N [2 (4 MORPHOLINYL)ETHYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL] N CYCLOPROPYL 2 (4 FLUOROPHENYL) PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (FLUOROPHENYL) N (4 METHOXYPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 [2 (CYCLOPENTYLAMINO)PYRIMIDIN 4 YL] 2 (4 FLUOROPHENYL) N MORPHOLIN 4 YLPYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 [2 (CYCLOPENTYLAMINO)PYRIMIDIN 4 YL] 2 (4 FLUOROPHENYL) N PYRROLIDIN 1 YLPYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 3 [[4 [7 (BUTYLAMINO) 2 (4 FLUOROPHENYL)PYRAZOLO[1,5 ALPHA]PYRIDIN 3 YL] 2 PYRIMIDINYL]AMINO] 1 PROPANOL; ACICLOVIR; AMINE; ANTIVIRUS AGENT; GW 3733; N ALLYL 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N BUTYL 2 (4 FLUOROPHENYL) 3 [2 [(2 PYRIDINYLMETHYL)AMINO] 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N BUTYL 2 (4 FLUOROPHENYL) 3 [2 [[2 (4 MORPHOLINYL)ETHYL]AMINO] 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N BUTYL 2 (4 FLUOROPHENYL) 3 [2 [[3 (1H IMIDAZOL 1 YL)PROPYL]AMINO] 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N BUTYL 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N BUTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL) PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N BUTYL 3 [2 (CYCLOPROPYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL) PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 2 (4 FLUOROPHENYL) 3 [2 (4 METHOXYANILINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 2 (4 FLUOROPHENYL) 3 [2 [[3 (4 MORPHOLINYL)PROPYL]AMINO] 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (4 FLUOROANILINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N,2 BIS(4 FLUOROPHENYL) 3 [2 [(4 FLUOROPHENYL)AMINO] 4 PYRIMIDINYL] PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; PYRAZOLE DERIVATIVE; PYRAZOLO[1,5 A]PYRIDINE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DERIVATIZATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; GENETIC VARIABILITY; HERPES SIMPLEX VIRUS 1; NONHUMAN; PROMOTER REGION; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION; TECHNIQUE; UNTRANSLATED REGION; VIRUS REPLICATION;

EID: 20044374521     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.01.044     Document Type: Article

References (29)

1. B. Roizman, and P.E. Pellett D.M. Knipe P.M. Howley Fields Virology Vol. 2 2001 Lippincott Williams and Wilkins Philadelphia, PA 2381
2. Corey, L.; Tyring, S.; Sacks, S.; Warren, T.; Beutner, K.; Patel, R.; Wald, A.; Mertz, G.; Paavonen, J. Abstract of papers, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA; American Society for Microbiology: Washington, DC, 2002; Abstract LB3
3. N.L. Oien, R.J. Brideau, and T.A. Hopkins Antimicrob. Agents Chemother. 46 2002 724
4. R.J. Brideau, M.L. Knechtel, and A. Huang Antiviral Res. 54 2002 19
5. M.W. Wathen Rev. Med. Virol. 12 2002 167
6. M. Jurk, R. Heil, and J. Vollmer Nat. Immunol. 3 2002 499
7. M.A. Stanley Clin. Exp. Dermatol. 27 2002 571
8. J.J. Crute, C.A. Grygon, K.D. Hargrave, B. Simoneau, A.-M. Faucher, G. Bolger, P. Kibler, M. Liuzzi, and M.G. Cordingley Nat. Med. 8 2002 386
9. G. Kleymann, R. Fischer, U.A.K. Betz, M. Hendrix, W. Bender, U. Schneider, G. Handke, and P. Eckenberg Nat. Med. 8 2002 392
10. B.A. Johns, K.S. Gudmundsson, E.M. Turner, S.H. Allen, D.K. Jung, C.J. Sexton, F.L. Boyd Jr., and M.R. Peel Tetrahedron 59 2003 9001
11. K.S. Gudmundsson, and B.A. Johns Org. Lett. 5 2003 1369
12. Sexton, C. J.; Selleseth, D. W.; Jansen, R. W., unpublished results
13. Alberti, M. J.; Baldwin, I. R.; Cheung, M.; Cockerill, S.; Flack, S.; Harris, P. A.; Jung, D. K.; Peckham, G.; Peel, M. R.; Stanford, J. B.; Stevens, K.; Veal, J. M. WO 02/16359, 2002; Chem. Abstr. 2002, 136, 200184
14. The representation of compounds follows the convention that specific compounds are numbered (1, 2, 3...) as they appear in the manuscript while generic structures containing variable groups 'R' are represented with letters (A, B, C...)
15. J.P. Wolfe, S. Wagaw, and S.L. Buchwald J. Am. Chem. Soc. 118 1996 7215
16. M.C. Harris, O. Geis, and S.L. Buchwald J. Org. Chem. 64 1999 6019
17. J.P. Wolfe, and S.L. Buchwald J. Org. Chem. 65 2000 1144
18. J.F. Hartwig Angew. Chem., Int. Ed. 37 1998 2046
19. An alternative approach to further functionalize methyl ketone 5 by treatment with dimethylformamide-dimethylacetal to form the vinylogous amide containing the 7-chloro substituent resulted in variable levels of 7-dimethylamino derived side products. Presumably this arises via direct nucleophilic displacement of the 7-chloro substituent by dimethylamine liberated from the DMF-DMA during extended reaction times. This could be minimized by use of dimethylformamide di-tert-butylacetal, which gave much reduced reaction times
20. R. Huisgen, R. Grashey, and R. Krischke Tetrahedron Lett. 3 1962 387
21. P.L. Anderson, J.P. Hasak, A.D. Kahle, N.A. Paolella, and M.J. Shapiro J. Heterocycl. Chem. 18 1981 1149
22. A. Akahane, H. Katayama, T. Mitsunaga, Y. Kita, T. Kusunoki, T. Terai, K. Yoshida, and Y. Shiokawa Bioorg. Med. Chem. Lett. 6 1996 2059
23. A. Zanka, R. Uematsu, Y. Morinaga, H. Yasuda, and H. Yamazaki Org. Process Res. Dev. 3 1999 389
24. A.J. Majeed, O. Antonsen, T. Benneche, and K. Undheim Tetrahedron 45 1989 993
25. B.L. Finkelstein J. Org. Chem. 57 1992 5538
26. T. Aboul-Fadl, S. Lober, and P. Gmeiner Synthesis 2000 1727
27. For GW3733; clog P = 6.7. Solubility in HCl (pH = 1.2) = 6.7 μg/mL. Phosphate-buffered saline (pH = 7.4) 1.2 μg/mL
28. 9) was made via a modification of methods described in R.A.B. Bannard, A.A. Casselman, W.F. Cockburn, and G.M. Brown Can. J. Chem. 36 1958 1541
29. For a general procedure for the synthesis of substituted guanidinium salts, see: R.B. Fearing, and S.W. Fox J. Am. Chem. Soc. 76 1954 4382